| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
08-03-2009, 06:11 PM
|
#1 | |||
|
||||
|
Magnate
|
High-tech drugs would get 12-yr market protection
The Associated Press Friday, July 31, 2009 5:21 PM http://www.washingtonpost.com/wp-dyn...073102957.html WASHINGTON -- A House committee has agreed to grant 12 years of market protection to high-tech drugs used to combat cancer, Parkinson's and other deadly diseases.
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller |
|||
|
 Reply With Quote
|
|
08-03-2009, 06:24 PM
|
#2 | |||
|
||||
|
Magnate
|
Biotech drug companies step up lobbying war
At stake is the nation's 46 billion biological drug market Associated Press, MSNBC, updated 1:11 p.m. PT, Mon., Aug 3, 2009 http://www.msnbc.msn.com/id/32273674...-capitol_hill/ WASHINGTON - With the nation's $46 billion biological drug market at stake, the war between makers of the pricey biotech medicines and their would-be generic competitors has involved millions of dollars in lobbying, thousands in campaign contributions and uncounted visits to members of Congress. And one noteworthy letter. The note from the private National Health Council, sent to House leaders drafting health overhaul legislation, said the plea was on behalf of "the more than 133 million Americans living with chronic diseases and disabilities and their family caregivers." It urged lawmakers to protect the makers of high-technology biological medicines against early competition from lower-cost generic copycats. The letter did not mention that nearly $1.2 million of the council's $2.3 million budget in 2007 came from the pharmaceutical industry's chief trade group and 16 companies that sell or are developing the brand-name biotech drugs.
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller Last edited by Stitcher; 08-03-2009 at 06:43 PM. |
|||
|
|
Reply With Quote
|
|
08-04-2009, 11:50 AM
|
#3 | ||
|
|||
|
New Member
|
The National Health Council has advocated for a regulatory pathway for biosimiliars that improves access to existing drug therapies while simultaneously promoting the development of new treatments. Our letter to Congress was posted on the Web in June. **
The AP described only part of our position – the part that calls for 10 years of data exclusivity similar to other international standards. The reporter did not address our call to use data exclusivity to encourage the development of treatments for conditions with limited or no treatments, such as ALS or lupus. In doing so he implied our position had been inappropriately influenced by drug manufacturers. Our policy on corporate relations publicly defines our relationship with business and industry. ** NHC has been clear in its cause to foster research & development that leads to breakthrough treatments so desperately needed by patients. Emily Noonan Manager, Communications and Marketing National Health Council |
||
|
|
Reply With Quote
|
| "Thanks for this!" says: | paula_w (08-05-2009) |
| Reply |
|
|
High-tech drugs would get 12-yr market protection
Linear Mode
